Description
CEND-1 (also known as Certepetide or LSTA1) is an investigational medication currently being studied in clinical trials for various cancers, including colorectal cancer. It is being evaluated in combination with standard chemotherapy regimens like FOLFIRINOX (a combination of 5-fluorouracil, leucovorin, irinotecan, and oxaliplatin), sometimes with the addition of panitumumab (a targeted therapy). The goal of these early-phase trials (Phase 1B/2A) is primarily to assess the safety and tolerability of CEND-1 when given alongside these established treatments. Researchers are looking to see if adding CEND-1 to standard care is safe and if it shows any signs of effectiveness in shrinking tumors or improving outcomes in patients with pancreatic, colon, or appendiceal cancers.
Mechanism of Action
CEND-1 is a peptide-based drug. In preclinical studies, it has shown the ability to inhibit the growth of certain cancer cells. The specific way CEND-1 works at a molecular level (its exact target) is still being investigated in clinical trials. Researchers are studying how it interacts with cancer cells and the tumor microenvironment to understand its potential anti-cancer effects.
Side Effects
Not all side effects are listed. Side effects vary by individual. Always consult your oncologist.